Nuvo Research announces director election results of its Annual General Meeting

MISSISSAUGA, ON, May 13, 2015 /CNW/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that at its 2015 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 1, 2015 were elected as directors of the Company.

The detailed results of the votes by proxy are as follows:

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel Chicoine	2,833,962	930,810	75.28	24.72
David A. Copeland	3,580,537	184,235	95.11	4.89
Anthony E. Dobranowski	3,628,522	136,250	96.38	3.62
Dr. Henrich R.K. Guntermann	3,619,959	144,813	96.15	3.85
Dr. Klaus von Lindeiner	3,624,109	140,663	96.26	3.74
John C. London	3,030,777	733,995	80.50	19.50
Dr. Jacques Messier	3,624,625	140,147	96.28	3.72
Dr. Theodore H. Stanley	3,627,257	137,515	96.35	3.65

About Nuvo Research Inc.
Nuvo (TSX:NRI) is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group.  The TPT Group currently has four commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and multiple drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin.  The Immunology Group has two commercial products and an immune system modulation platform that supports the development of drug products that modulate chronic inflammation processes resulting in a therapeutic benefit.  For additional company information visit www.nuvoresearch.com.

SOURCE Nuvo Research Inc.

Investor Relations, Email: [email protected]